Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
48-week dose-ranging study of BI 655066 vs ustekinumab in chronic plaque psoriasis
2012-004384-48Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of risankizumab in psoriasis, plaque psoriasis, sponsored by Boehringer Ingelheim. Started Nov 2013; status: completed.
02
Drugs
risankizumab
03
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on 2012-004384-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004384-48.